The neutrophil‐to‐lymphocyte ratio at the start of the second course during atezolizumab plus bevacizumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysisSho Matoya, Yoshihito Nagura, Yuta Suzuki et al.|Hepatology Research|2023Cited by 22